

**THE TRENDLINES GROUP LTD.**

(Incorporated in Israel)

(Company Registration No. 513970947)

---

**Execution of a Definitive Agreement between the Company, B. Braun Melsungen AG and Trendlines Medical Singapore Pte. Ltd.**

---

The board of directors (the “**Board**”) of The Trendlines Group Ltd. (the “**Company**” and together with its subsidiaries and associated companies, the “**Group**”) refers to the Company’s announcement dated 8 September 2016 regarding the execution by the Company of a non-binding Memorandum of Understanding with B. Braun Melsungen AG (“**Braun**”), a German medical and pharmaceutical device company, which set forth the principal terms to be included in a definitive agreement (the “**Definitive Agreement**”) to be entered into between the Company and Braun in connection with their investment in, and the operation of, a wholly owned subsidiary in Singapore, Trendlines Medical Singapore Pte. Ltd. (“**Trendlines Medical Singapore**”).

The Board wishes to announce that the Company has signed the Definitive Agreement with Braun and Trendlines Medical Singapore pursuant to which Braun and the Company shall subscribe for and shall be allotted and issued new ordinary shares of Trendlines Medical Singapore.

Following the said subscription and allotment, the Company shall hold 356,667 ordinary shares (approximately 79.26%) of the issued share capital of Trendlines Medical Singapore and Braun shall hold 93,333 ordinary shares (approximately 20.74%) of the issued share capital of Trendlines Medical Singapore.

The Company’s share of the subscription amounting to S\$2,500,000 is funded from the Company’s initial public offering dated 16 November 2015 (the “**IPO**”) and is within the limits set under the intended use “Expansion of operations into new markets” detailed on page 69 of the IPO. All shares shall be allotted by the end of the financial year ending 31 December 2016.

The parties waived the condition set out in the Company’s announcement dated 8 September 2016 that the execution of the Definitive Agreement is subject to confirmation of funding from the Singapore Government.

Following the above subscription, Ms. Anna Maria Braun, President of Braun Asia Pacific and a member of the Braun management board, and Professor Dr. Boris Hofmann, Director of Business Development for Braun’s Aesculap Division, will join the board of directors of the Trendlines Medical Singapore. The other board members of Trendlines Medical Singapore currently appointed by the Company are the directors from Trendlines, Mr Zeev Bronfeld, Mr Stephen Louis Rhodes, and Mr David Todd Dollinger as well as the chief executive officer of Trendlines Medical Singapore, Mr Eric Loh.

In addition, either the Company or a third-party investor shall in the course of the next few months subscribe for and purchase an additional number of shares of Trendlines Medical Singapore at the same price per share to be paid by the Company for its investment as detailed above. Further information will be disclosed when the additional subscription shall take place.

The Company's aforesaid investment in Trendlines Medical Singapore is not expected to have any material impact on the earnings per share and net tangible asset per share of the Group for the financial year ending 31 December 2016.

#### **Interest of Directors and Substantial Shareholders**

None of the Company's Directors, substantial shareholders and/or any of their respective associates has any interest, direct or indirect (other than through their shareholdings in the Company), in the above transaction.

#### **BY ORDER OF THE BOARD THE TRENDLINES GROUP LTD.**

Yosef Ron,  
Joint Company Secretary

21 December 2016

---

*The Trendlines Group Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 26 November 2015. The initial public offering of the Company was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**").*

*This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.*

*This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.*